Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2016

View Archived Issues

Cydan announces launch of orphan drug company Imara

Ganaxolone granted U.S. orphan drug desgination in status epilepticus

NewLink awarded DoD contract for filovirus vaccines

NICE recommends Translarna for Duchenne muscular dystrophy in England

Elorac acquires Gideon Pharmaceuticals

ABT-493 given with ABT-530 in MAGELLAN-I hepatitis C study

Heptares and Kymab collaborate on novel antibodies targeting GPCRs

Gilead's GS-9674 shows promise in treating nonalcoholic steatohepatitis

FDA approves Gilotrif for advanced squamous cell carcinoma of the lung

Boehringer Ingelheim exercises option to oncology target under Oxford BioTherapeutics collaboration

FDA issues complete response letter for Mycapssa in acromegaly

EMA committee extends safety review of direct-acting antivirals

Enrollment complete in Japanese phase I/II study of HGF gene therapy in primary lymphedema

Constellation Pharmaceuticals discovers novel EZH2 methyltransferase inhibitors

Infinity Pharmaceuticals develops PI3Kgamma inhibitors

Proximagen reports development of SSAO inhibitors

Flatley Discovery Lab patents CFTR channel correctors

Trinity College Dublin divulges compounds for multiple sclerosis

A*STAR reports antimicrobial imidazolium compounds

AC Immune and Biogen collaborate in neurodegenerative diseases

Vernalis' CCP-07 completes pivotal bioavailability study

ExxPharma Therapeutics and Halo Pharmaceutical announce collaboration

AmpliPhi terminates exclusive channel collaboration with Intrexon

WHO advisory group recommends use of Dengvaxia in endemic countries

FDA orphan drug status conferred on Debio-1143 for ovarian cancer

Armodafinil improves daytime somnolence and psychiatric features associated with DLB

Bioprojet Pharma's Wakix approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...